This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and ...

Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...

Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating ...

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.